ArticleGenome medicine2013
The emergence of top-down proteomics in clinical research.
Article in Genome medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06900270 (Cross-sectional Cohort Analysis of Plasma Proteomics in Coronary Artery Disease and Plasma Metabolomics in Coronary Artery Disease), which is not on this map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cross-sectional Cohort Analysis of Plasma Proteomics in Coronary Artery Disease and Plasma Metabolomics in Coronary Artery Disease: Comparative Study Between Patients with Obstructive (≥ 50%), Non-obstructive (< 50%) and No Lesions
Who cites it
55 citing papers in PubMed, 99 citations in OpenAlex.
- Early maturation of host antimicrobial peptide defences is associated with host-pathogen coexistence.Nature chemical biology · 2026Article
- Article
- Prediction of transformative breakthroughs in biomedical research.bioRxiv : the preprint server for biology · 2025Article
- Bacterial Proteomics and Antibiotic Resistance Identification: Is Single-Cell Analysis a Worthwhile Pursuit?Pathogens (Basel, Switzerland) · 2025Review
- Immunoaffinity Intact Top-Down Mass Spectrometry for Quantification of Neuron-Specific Enolase Gamma, a Low-Abundance Protein Biomarker.Analytical chemistry · 2025Article
- Multi-omics approaches for biomarker discovery and precision diagnosis of prediabetes.Frontiers in endocrinology · 2025Review
- Puzzle of Proteoform Variety-Where Is a Key?Proteomes · 2024Article
- Proteoform-Resolved Profiling of Plasminogen Activation Reveals Novel Abundant Phosphorylation Site and Primary N-Terminal Cleavage Site.Molecular & cellular proteomics : MCP · 2024Article
- Review
- Top-Down Proteomics and the Challenges of True Proteoform Characterization.Journal of proteome research · 2023Review
- A global view of the human post-translational modification landscape.The Biochemical journal · 2023Review
- Multidimensional Separations in Top-Down Proteomics.Analytical science advances · 2023Article
- Global profiling of phosphorylation-dependent changes in cysteine reactivity.Nature methods · 2022Article
- An immuno-enrichment free, validated quantification of tau protein in human CSF by LC-MS/MS.PloS one · 2022Article
- Robust unsupervised deconvolution of linear motifs characterizes 68 protein modifications at proteome scale.Scientific reports · 2021Article
- Machine learning-aided protein identification from multidimensional signatures.Lab on a chip · 2021Article
- Enhancing Top-Down Proteomics of Brain Tissue with FAIMS.Journal of proteome research · 2021Article
- Robustness and Ruggedness of Isoelectric Focusing and Superficially Porous Liquid Chromatography with Fourier Transform Mass Spectrometry.Journal of the American Society for Mass Spectrometry · 2021Article
- Uniting Native Capillary Electrophoresis and Multistage Ultraviolet Photodissociation Mass Spectrometry for Online Separation and Characterization ofAnalytical chemistry · 2020Article
- Histone H1 Post-Translational Modifications: Update and Future Perspectives.International journal of molecular sciences · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Proteomic technology has advanced steadily since the development of 'soft-ionization' techniques for mass-spectrometry-based molecular identification more than two decades ago. Now, the large-scale analysis of proteins (proteomics) is a mainstay of biological research and clinical translation, with researchers seeking molecular diagnostics, as well as protein-based markers for personalized medicine. Proteomic strategies using the protease trypsin (known as bottom-up proteomics) were the first to be developed and optimized and form the dominant approach at present. However, researchers are now beginning to understand the limitations of bottom-up techniques, namely the inability to characterize and quantify intact protein molecules from a complex mixture of digested peptides. To overcome these limitations, several laboratories are taking a whole-protein-based approach, in which intact protein molecules are the analytical targets for characterization and quantification. We discuss these top-down techniques and how they have been applied to clinical research and are likely to be applied in the near future. Given the recent improvements in mass-spectrometry-based proteomics and stronger cooperation between researchers, clinicians and statisticians, both peptide-based (bottom-up) strategies and whole-protein-based (top-down) strategies are set to complement each other and help researchers and clinicians better understand and detect complex disease phenotypes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.